The Defocus Incorporated Multiple Segments (DIMS) Spectacle Lens developed by the Hong Kong Polytechnic University (PolyU) slowed down myopia progress by 60 percent in participating children; myopic progression halted completely in 21.5 percent of subjects. This lens will be launched in summer 2018, offering a non-contact, spectacle lens solution to myopic children.
The lens was designed by Professor Carly Lam, Professor of the School of Optometry at PolyU, and Professor To Chi-ho, Henry G. Leong Professor in Elderly Vision Health and Head of the School.
The DIMS Spectacle Lens comprises a central optical zone for correcting refractive error (i.e. myopia and astigmatism) and multiple segments of constant myopic defocus surrounding the central zone extending to mid-periphery of the lens. It provides clear vision and myopic defocus for vision correction simultaneously for the wearer at all viewing distances. In doing so, the lens makes use of the natural homeostatic mechanism known as emmetropization, whereby the eyeball adapts and shapes to receive focused images as it does for normal vision.
"We have tried to incorporate myopic defocus optics into different treatment modalities, such as contact lens. For spectacle lens, the challenge is the eye will move behind the spectacle lens and therefore the myopic defocus optics has to be incorporated all over the lens," said Professor To.
"With the DIMS Spectacle Lens, we are able to put in many micro-lenses all over the surface of the ophthalmic lens. When the eye moves around different regions of the spectacle lens, the eye still experiences a constant amount of myopic defocus," he added.
A total of 160 Chinese children aged eight to 13 with myopia from one to five diopters (D), and astigmatism and anisometropia of 1.5D or less completed a randomised double-blinded clinical trial from August 2014 to July 2017.
Seventy-nine and 81 children were randomly assigned to wear the DIMS Spectacle Lenses (treatment group) and the single vision spectacle lenses (control group) respectively. The mean myopic progression of the treatment group over two years was 0.38D whereas the control group was 0.93D.
Myopia occurs when the eyeball is too long relative to the focusing power of the cornea and lens of the eye. Light focuses in front of the retina rather than on it, making distant objects appear blurry. In the trial, the mean increase in eyeball axial length of the treatment group was 0.21mm while the control group was 0.53mm. In other words, children wearing the DIMS Spectacle Lenses had significantly less myopic progression by 59 percent, and axial elongation by 60 percent, as compared with those wearing the single vision lenses.
For the individual, in addition to slow myopic progression, the study shows that wearing DIMS Spectacle Lens stops the progression of myopia in some children. 21.5 percent of children in the treatment group had no myopic progression whereas only 7.4 percent of children in the control group had no myopic progression.
Additionally, 13.9 percent of children in the treatment group had no change in axial length changes whereas the control group recorded zero. The children in the treatment group also indicated that the DIMS Spectacle Lens could provide comfortable, good vision at short and long distances, and good perception of depth same as single vision spectacle lens.
"High myopia can cause retinal complications. The serious case could be a retinal detachment that may result in permanent blindness or visual impairment. The DIMS Spectacle Lens helps safeguard the vision of children," said Professor Lam.
The DIMS Spectacle Lens is licensed to a lens company experienced in eyeglass lenses and will be available in the market in this summer.
Explore further: Optometry experts prove the effectiveness of orthokeratology in myopic control